Predictive value of procalcitonin for infection of patients with type‑2 diabetes mellitus

Wang,Xinshui; Sun,Yanbei; Shao,Xiaonan

doi:10.3892/etm.2019.7611

Predictive value of procalcitonin for infection of patients with type‑2 diabetes mellitus

Authors:
- Xinshui Wang
- Yanbei Sun
- Xiaonan Shao
View Affiliations

Affiliations: Department of Endocrinology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213003, P.R. China
Published online on: May 24, 2019 https://doi.org/10.3892/etm.2019.7611
Pages: 722-728

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the predictive value of procalcitonin (PCT) for infection in patients with type 2 diabetes mellitus (T2DM). A retrospective analysis of 178 patients with T2DM who were divided into non‑infection, local infection and sepsis groups was conducted; in conjunction with 33 healthy control patients. Clinicopathological characteristics and inflammatory indicators were compared between the four groups. Patients in the non‑infection group exhibited significantly higher PCT levels compared with healthy controls (P=0.002). In addition, PCT, C‑reactive protein (CRP), white blood cell count and neutrophil percent were significantly different amongst patients with T2MD across different infection groups (all P<0.001) with the following rank order: Sepsis group > local infection group > non‑infection group (all P<0.05). In addition, the following observations were made: i) PCT and CRP demonstrated larger areas under the curve (AUC) for predicting local infection (0.804 and 0.741, respectively); ii) PCT displayed lower sensitivity of only 21.8% at its classical cutoff value (0.500 ng/ml) whereas CRP exhibited higher sensitivity and specificity at 64.1 and 76.1%, respectively, at its classical cutoff value (10.0 mg/l); and iii) PCT exhibited the largest AUC (0.914) for predicting sepsis with high sensitivity and specificity (86.4 and 84.5%, respectively) at its cutoff value (0.990 ng/ml). Patients with T2DM without infection demonstrated higher baseline PCT levels. The present study clarified the value of PCT in predicting infection of T2DM patients. The application of PCT to predict local infection in patients with T2DM was identified to be inferior to CRP, but its ability to predict sepsis was concluded to be the best when compared with CRP, white blood cell count and neutrophil percent.

View Figures

View References

1	Whiting DR, Guariguata L, Weil C and Shaw J: IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 94:311–321. 2011. View Article : Google Scholar : PubMed/NCBI
2	Rahelic D: 7th edition of IDF Diabetes Atlas-call for Immediate Action. Lijec Vjesn. 138:57–58. 2016.(In Croatian). PubMed/NCBI
3	Shah BR and Hux JE: Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 26:510–513. 2003. View Article : Google Scholar : PubMed/NCBI
4	Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI and Rutten GE: Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 41:281–288. 2005. View Article : Google Scholar : PubMed/NCBI
5	Korbel L and Spencer JD: Diabetes mellitus and infection: An evaluation of hospital utilization and management costs in the United States. J Diabetes Complicat. 29:192–195. 2015. View Article : Google Scholar : PubMed/NCBI
6	Hine JL, de Lusignan S, Burleigh D, Pathirannehelage S, McGovern A, Gatenby P, Jones S, Jiang D, Williams J, Elliot AJ, et al: Association between glycaemic control and common infections in people with Type 2 diabetes: A cohort study. Diabetic Med. 34:551–557. 2017. View Article : Google Scholar : PubMed/NCBI
7	Florio W, Morici P, Ghelardi E, Barnini S and Lupetti A: Recent advances in the microbiological diagnosis of bloodstream infections. Crit Rev Microbiol. 44:351–370. 2018. View Article : Google Scholar : PubMed/NCBI
8	Vashist SK, Venkatesh AG, Marion Schneider E, Beaudoin C, Luppa PB and Luong JH: Bioanalytical advances in assays for C-reactive protein. Biotechnol Adv. 34:272–290. 2016. View Article : Google Scholar : PubMed/NCBI
9	Muller B and Becker KL: Procalcitonin: How a hormone became a marker and mediator of sepsis. Swiss Med Wkly. 131:595–602. 2001.PubMed/NCBI
10	Karzai W, Oberhoffer M, Meier-Hellmann A and Reinhart K: Procalcitonin-a new indicator of the systemic response to severe infections. Infect. 25:329–334. 1997. View Article : Google Scholar
11	Snider RH Jr, Nylen ES and Becker KL: Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Invest Med. 45:552–560. 1997.
12	Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:539–553. 1998. View Article : Google Scholar : PubMed/NCBI
13	Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL and Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 29:530–538. 2003. View Article : Google Scholar : PubMed/NCBI
14	Wellen KE and Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest. 115:1111–1119. 2005. View Article : Google Scholar : PubMed/NCBI
15	Jafar N, Edriss H and Nugent K: The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci. 351:201–211. 2016. View Article : Google Scholar : PubMed/NCBI
16	Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, Hughes TM, Craft S, Freedman BI, Bowden DW, et al: Diabetic Microvascular Disease: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 102:4343–4410. 2017. View Article : Google Scholar : PubMed/NCBI
17	Stegenga ME, van der Crabben SN, Blumer RM, Levi M, Meijers JC, Serlie MJ, Tanck MW, Sauerwein HP and van der Poll T: Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood. 112:82–89. 2008. View Article : Google Scholar : PubMed/NCBI
18	Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C and Remuzzi G: Leukocyte- endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J Clin Invest. 101:1905–1915. 1998. View Article : Google Scholar : PubMed/NCBI
19	Cohen G, Ilic D, Raupachova J and Horl WH: Resistin inhibits essential functions of polymorphonuclear leukocytes. J Immunol. 181:3761–3768. 2008. View Article : Google Scholar : PubMed/NCBI
20	Becker KL, Nylen ES, White JC, Muller B and Snider RH Jr: Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: A journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 89:1512–1525. 2004. View Article : Google Scholar : PubMed/NCBI
21	Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G and Bakker SJ: Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome. J Clin Endocrinol Metab. 95:E26–E31. 2010. View Article : Google Scholar : PubMed/NCBI
22	James MT, Quan H, Tonelli M, Manns BJ, Faris P, Laupland KB and Hemmelgarn BR: CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis. 54:24–32. 2009. View Article : Google Scholar : PubMed/NCBI
23	James MT, Laupland KB, Tonelli M, Manns BJ, Culleton BF and Hemmelgarn BR: Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Inter Med. 168:2333–2339. 2008. View Article : Google Scholar
24	Davenport A: Peritonitis remains the major clinical complication of peritoneal dialysis: The London, UK, peritonitis audit 2002–2003. Perit Dial Int. 29:297–302. 2009.PubMed/NCBI
25	Mactier R: Peritonitis is still the achilles' heel of peritoneal dialysis. Perit Dial Int. 29:262–266. 2009.PubMed/NCBI
26	Azoulay E, Chevret S, Didier J, Barboteu M, Bornstain C, Darmon M, Le Gall JR, Vexiau P and Schlemmer B: Infection as a trigger of diabetic ketoacidosis in intensive care-unit patients. Clin Infect Dis. 32:30–35. 2001. View Article : Google Scholar : PubMed/NCBI
27	Joshi N, Caputo GM, Weitekamp MR and Karchmer AW: Infections in patients with diabetes mellitus. New Engl J Med. 341:1906–1912. 1999. View Article : Google Scholar : PubMed/NCBI
28	Marrie TJ: Bacteraemic pneumococcal pneumonia: A continuously evolving disease. J Infect. 24:247–255. 1992. View Article : Google Scholar : PubMed/NCBI
29	Nichols GA, Brodovicz KG, Kimes TM, Deruaz-Luyet A and Bartels DB: Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. J Diabetes Complications. 31:1587–1591. 2017. View Article : Google Scholar : PubMed/NCBI
30	Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R and Merlini A: Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 31:1737–1741. 2003. View Article : Google Scholar : PubMed/NCBI
31	Castelli GP, Pognani C, Meisner M, Stuani A, Bellomi D and Sgarbi L: Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care. 8:R234–R242. 2004. View Article : Google Scholar : PubMed/NCBI
32	Schuetz P, Albrich W, Christ-Crain M, Chastre J and Mueller B: Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther. 8:575–587. 2010. View Article : Google Scholar : PubMed/NCBI
33	Lee SH, Chan RC, Wu JY, Chen HW, Chang SS and Lee CC: Diagnostic value of procalcitonin for bacterial infection in elderly patients-a systemic review and meta-analysis. Int J Clin Pract. 67:1350–1357. 2013. View Article : Google Scholar : PubMed/NCBI
34	Park JH, Kim DH, Jang HR, Kim MJ, Jung SH, Lee JE, Huh W, Kim YG, Kim DJ and Oh HY: Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: A cross-sectional study. Crit Care. 18:6402014. View Article : Google Scholar : PubMed/NCBI
35	Brechot N, Hekimian G, Chastre J and Luyt CE: Procalcitonin to guide antibiotic therapy in the ICU. Int J Antimicrob Agents. 46:S19–S24. 2015. View Article : Google Scholar : PubMed/NCBI
36	Tan BH, Png ME, Yeo CP and Wong GC: Procalcitonin in febrile neutropenia-timing is important. Support Care Cancer. 22:583–584. 2014. View Article : Google Scholar : PubMed/NCBI
37	Bodmann KF, Schenker M, Heinlein W and Wilke MH: Procalcitonin as a tool for the assessment of successful therapy of severe sepsis: An analysis using clinical routine data. Med Klin Intensivmed Notfmed. 113:533–541. 2016. View Article : Google Scholar : PubMed/NCBI
38	Davies J: Procalcitonin. J Clin Pathol. 68:675–679. 2015. View Article : Google Scholar : PubMed/NCBI
39	Claeys R, Vinken S, Spapen H, ver Elst K, Decochez K, Huyghens L and Gorus FK: Plasma procalcitonin and C-reactive protein in acute septic shock: Clinical and biological correlates. Crit Care Med. 30:757–762. 2002. View Article : Google Scholar : PubMed/NCBI
40	Sierra R, Rello J, Bailen MA, Benitez E, Gordillo A, Leon C and Pedraza S: C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. Intens Care Med. 30:2038–2045. 2004. View Article : Google Scholar